The Europe epilepsy drugs market was valued at US$ 1,941.16 million in 2022 and is expected to reach US$ 2,626.05 million by 2030; it is estimated to grow at a CAGR of 3.8% from 2022 to 2030.
Increasing Number of Elderly People Fuels the Europe Epilepsy Drugs Market
Epilepsy is one of the prevalent neurological disorders affecting the geriatric population. According to the National Center for Biotechnology Information, epilepsy is the third most common neurological disorder affecting the elderly after dementia and stroke. The incidence of epilepsy is increasing in older adults, partly because of the growing prevalence of stroke, brain tumors, and dementia. Considering that modern society is aging, the overall prevalence and incidence of epilepsy are expected to rise.
The Eurostat statistics indicate that over one-fifth (21.1%) of the European population was aged 65 or more in 2022. According to an article published by UpToDate Inc. in August 2021, the incidence rate of epilepsy rises with age and is highest among patients aged 75 and above.
Therefore, due to the growing geriatric population, there is notable surge in conditions such as epilepsy owing to which the market for epilepsy drugs witnesses a significant growth.
Europe Epilepsy Drugs Market Overview
The Europe epilepsy drugs market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the epilepsy drugs market. The European epilepsy drugs market is expected to witness significant growth during the forecast period due to factors such as the significant growth in elderly population, approvals of new drugs by regulatory authorities, increase in funding by governments to improve and develop effective drugs and treatments for seizures in the region.
Europe Epilepsy Drugs Market Revenue and Forecast to 2030 (US$ Million)
Europe Epilepsy Drugs Market Segmentation
The Europe epilepsy drugs market is segmented into treatment, distribution channel and country.
Based on treatment, the Europe epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held the largest share in 2022.
In terms of distribution channel, the Europe epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held the largest share in 2022.
Based on country, the Europe epilepsy drugs market is segmented Germany, the UK, France, Italy, Spain, and the Rest of Europe. The UK dominated the Europe epilepsy drugs market in 2022.
Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, Teva Pharmaceutical Industries Ltd, and UCB SA are some of the leading companies operating in the Europe epilepsy drugs market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 1,941.16 Million |
| Market Size by 2030 | US$ 2,626.05 Million |
| CAGR (2022 - 2030) | 3.8% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Treatment
|
|
Regions and Countries Covered
|
|
| Europe | UK, Germany, France, Russia, Italy, Rest of Europe |
| Market leaders and key company profiles |
|
1. Abbott Laboratories
2. Alkem Laboratories Ltd
3. GSK Plc
4. Novartis AG
5. Pfizer Inc
6. Sanofi SA
7. Teva Pharmaceutical Industries Ltd
8. UCB SA
The Europe Epilepsy Drugs Market is valued at US$ 1,941.16 Million in 2022, it is projected to reach US$ 2,626.05 Million by 2030.
As per our report Europe Epilepsy Drugs Market, the market size is valued at US$ 1,941.16 Million in 2022, projecting it to reach US$ 2,626.05 Million by 2030. This translates to a CAGR of approximately 3.8% during the forecast period.
The Europe Epilepsy Drugs Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Epilepsy Drugs Market report:
The Europe Epilepsy Drugs Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Epilepsy Drugs Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Epilepsy Drugs Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For Europe Epilepsy Drugs Market
